OSE Immunotherapeutics SA

09/16/2021 | Press release | Distributed by Public on 09/16/2021 10:06

Boehringer Ingelheim and OSE Immunotherapeutics Present Phase 1 Results with First-in-Class SIRPα Inhibitor BI 765063 in Advanced Solid Tumors at ESMO 2021